Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents-How P. aeruginosa Can Escape Antibiotics.

Ciofu O, Tolker-Nielsen T.

Front Microbiol. 2019 May 3;10:913. doi: 10.3389/fmicb.2019.00913. eCollection 2019. Review.

2.

Antibiotic therapy as personalized medicine - general considerations and complicating factors.

Moser C, Lerche CJ, Thomsen K, Hartvig T, Schierbeck J, Jensen PØ, Ciofu O, Høiby N.

APMIS. 2019 May;127(5):361-371. doi: 10.1111/apm.12951. Review.

PMID:
30983040
3.

P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage-ciprofloxacin combination.

Henriksen K, Rørbo N, Rybtke ML, Martinet MG, Tolker-Nielsen T, Høiby N, Middelboe M, Ciofu O.

Pathog Dis. 2019 Mar 1;77(2). pii: ftz011. doi: 10.1093/femspd/ftz011.

PMID:
30821815
4.

Hyperbaric oxygen treatment increases killing of aggregating Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Møller SA, Jensen PØ, Høiby N, Ciofu O, Kragh KN, Bjarnsholt T, Kolpen M.

J Cyst Fibros. 2019 Jan 30. pii: S1569-1993(19)30011-6. doi: 10.1016/j.jcf.2019.01.005. [Epub ahead of print]

PMID:
30711384
5.

Formation of Pseudomonas aeruginosa inhibition zone during tobramycin disk diffusion is due to transition from planktonic to biofilm mode of growth.

Høiby N, Henneberg KÅ, Wang H, Stavnsbjerg C, Bjarnsholt T, Ciofu O, Johansen UR, Sams T.

Int J Antimicrob Agents. 2019 May;53(5):564-573. doi: 10.1016/j.ijantimicag.2018.12.015. Epub 2019 Jan 5.

6.

Adaptation of Pseudomonas aeruginosa to the chronic phenotype by mutations in the algTmucABD operon in isolates from Brazilian cystic fibrosis patients.

Candido Caçador N, Paulino da Costa Capizzani C, Gomes Monteiro Marin Torres LA, Galetti R, Ciofu O, da Costa Darini AL, Høiby N.

PLoS One. 2018 Nov 29;13(11):e0208013. doi: 10.1371/journal.pone.0208013. eCollection 2018.

7.

Evolution of Antibiotic Resistance in Biofilm and Planktonic Pseudomonas aeruginosa Populations Exposed to Subinhibitory Levels of Ciprofloxacin.

Ahmed MN, Porse A, Sommer MOA, Høiby N, Ciofu O.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00320-18. doi: 10.1128/AAC.00320-18. Print 2018 Aug.

8.

IgG avidity to Pseudomonas aeruginosa over the course of chronic lung biofilm infection in cystic fibrosis.

Mauch RM, Nørregaard LL, Ciofu O, Levy CE, Høiby N.

J Cyst Fibros. 2018 May;17(3):356-359. doi: 10.1016/j.jcf.2017.09.004. Epub 2017 Oct 12.

PMID:
29032178
9.

Hyperbaric Oxygen Sensitizes Anoxic Pseudomonas aeruginosa Biofilm to Ciprofloxacin.

Kolpen M, Lerche CJ, Kragh KN, Sams T, Koren K, Jensen AS, Line L, Bjarnsholt T, Ciofu O, Moser C, Kühl M, Høiby N, Jensen PØ.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01024-17. doi: 10.1128/AAC.01024-17. Print 2017 Nov.

10.

Diagnosis of biofilm infections in cystic fibrosis patients.

Høiby N, Bjarnsholt T, Moser C, Jensen PØ, Kolpen M, Qvist T, Aanaes K, Pressler T, Skov M, Ciofu O.

APMIS. 2017 Apr;125(4):339-343. doi: 10.1111/apm.12689. Review.

PMID:
28407432
11.

Antibiotic treatment of biofilm infections.

Ciofu O, Rojo-Molinero E, Macià MD, Oliver A.

APMIS. 2017 Apr;125(4):304-319. doi: 10.1111/apm.12673. Review.

PMID:
28407419
12.

Real-Time Monitoring of nfxB Mutant Occurrence and Dynamics in Pseudomonas aeruginosa Biofilm Exposed to Subinhibitory Concentrations of Ciprofloxacin.

Zaborskyte G, Andersen JB, Kragh KN, Ciofu O.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02292-16. doi: 10.1128/AAC.02292-16. Print 2017 Mar.

13.

Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment.

Fernández-Barat L, Ciofu O, Kragh KN, Pressler T, Johansen U, Motos A, Torres A, Hoiby N.

J Cyst Fibros. 2017 Mar;16(2):222-229. doi: 10.1016/j.jcf.2016.08.005. Epub 2016 Sep 17.

14.

Proteome-wide antigen discovery of novel protective vaccine candidates against Staphylococcus aureus infection.

Rasmussen KJ, Mattsson AH, Pilely K, Asferg CA, Ciofu O, Vitved L, Koch C, Kemp M.

Vaccine. 2016 Aug 31;34(38):4602-4609. doi: 10.1016/j.vaccine.2016.07.016. Epub 2016 Aug 3.

PMID:
27496278
15.

The phenotypic evolution of Pseudomonas aeruginosa populations changes in the presence of subinhibitory concentrations of ciprofloxacin.

Wassermann T, Meinike Jørgensen K, Ivanyshyn K, Bjarnsholt T, Khademi SM, Jelsbak L, Høiby N, Ciofu O.

Microbiology. 2016 May;162(5):865-75. doi: 10.1099/mic.0.000273. Epub 2016 Mar 7.

PMID:
26953154
16.

Genome Sequence of Pseudomonas aeruginosa Strain DK1-NH57388A, a Stable Mucoid Cystic Fibrosis Isolate.

Norman A, Ciofu O, Amador CI, Høiby N, Jelsbak L.

Genome Announc. 2016 Feb 25;4(1). pii: e00008-16. doi: 10.1128/genomeA.00008-16.

17.

OligoG CF-5/20 Disruption of Mucoid Pseudomonas aeruginosa Biofilm in a Murine Lung Infection Model.

Hengzhuang W, Song Z, Ciofu O, Onsøyen E, Rye PD, Høiby N.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2620-6. doi: 10.1128/AAC.01721-15. Print 2016 May.

18.

Reinforcement of the bactericidal effect of ciprofloxacin on Pseudomonas aeruginosa biofilm by hyperbaric oxygen treatment.

Kolpen M, Mousavi N, Sams T, Bjarnsholt T, Ciofu O, Moser C, Kühl M, Høiby N, Jensen PØ.

Int J Antimicrob Agents. 2016 Feb;47(2):163-7. doi: 10.1016/j.ijantimicag.2015.12.005. Epub 2015 Dec 29.

PMID:
26774522
19.

Within-host microevolution of Pseudomonas aeruginosa in Italian cystic fibrosis patients.

Marvig RL, Dolce D, Sommer LM, Petersen B, Ciofu O, Campana S, Molin S, Taccetti G, Johansen HK.

BMC Microbiol. 2015 Oct 19;15:218. doi: 10.1186/s12866-015-0563-9.

20.

Increased bactericidal activity of colistin on Pseudomonas aeruginosa biofilms in anaerobic conditions.

Kolpen M, Appeldorff CF, Brandt S, Mousavi N, Kragh KN, Aydogan S, Uppal HA, Bjarnsholt T, Ciofu O, Høiby N, Jensen PØ.

Pathog Dis. 2016 Feb;74(1):ftv086. doi: 10.1093/femspd/ftv086. Epub 2015 Oct 12.

21.

Diversity of metabolic profiles of cystic fibrosis Pseudomonas aeruginosa during the early stages of lung infection.

Jørgensen KM, Wassermann T, Johansen HK, Christiansen LE, Molin S, Høiby N, Ciofu O.

Microbiology. 2015 Jul;161(7):1447-62. doi: 10.1099/mic.0.000093. Epub 2015 Apr 13.

PMID:
25873584
22.

Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.

Ciofu O, Tolker-Nielsen T, Jensen PØ, Wang H, Høiby N.

Adv Drug Deliv Rev. 2015 May;85:7-23. doi: 10.1016/j.addr.2014.11.017. Epub 2014 Dec 2. Review.

PMID:
25477303
23.

The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection -- a pilot study.

Skov M, Pressler T, Lykkesfeldt J, Poulsen HE, Jensen PØ, Johansen HK, Qvist T, Kræmer D, Høiby N, Ciofu O.

J Cyst Fibros. 2015 Mar;14(2):211-8. doi: 10.1016/j.jcf.2014.09.015. Epub 2014 Oct 23.

24.

Physiological levels of nitrate support anoxic growth by denitrification of Pseudomonas aeruginosa at growth rates reported in cystic fibrosis lungs and sputum.

Line L, Alhede M, Kolpen M, Kühl M, Ciofu O, Bjarnsholt T, Moser C, Toyofuku M, Nomura N, Høiby N, Jensen PØ.

Front Microbiol. 2014 Oct 24;5:554. doi: 10.3389/fmicb.2014.00554. eCollection 2014.

25.

Antioxidant supplementation for lung disease in cystic fibrosis.

Ciofu O, Lykkesfeldt J.

Cochrane Database Syst Rev. 2014 Aug 7;(8):CD007020. doi: 10.1002/14651858.CD007020.pub3. Review.

PMID:
25102015
26.

Detection of NDM-2-producing Acinetobacter baumannii and VIM-producing Pseudomonas aeruginosa in Palestine.

Sjölander I, Hansen F, Elmanama A, Khayyat R, Abu-Zant A, Hussein A, Taha AA, Hammerum AM, Ciofu O.

J Glob Antimicrob Resist. 2014 Jun;2(2):93-97. doi: 10.1016/j.jgar.2013.11.002. Epub 2013 Nov 23.

PMID:
27873597
27.

Pharmacokinetics and pharmacodynamics of antibiotics in biofilm infections of Pseudomonas aeruginosa in vitro and in vivo.

Hengzhuang W, Høiby N, Ciofu O.

Methods Mol Biol. 2014;1147:239-54. doi: 10.1007/978-1-4939-0467-9_17.

PMID:
24664838
28.

Effect of long-term voluntary exercise wheel running on susceptibility to bacterial pulmonary infections in a mouse model.

van de Weert-van Leeuwen PB, de Vrankrijker AM, Fentz J, Ciofu O, Wojtaszewski JF, Arets HG, Hulzebos HJ, van der Ent CK, Beekman JM, Johansen HK.

PLoS One. 2013 Dec 23;8(12):e82869. doi: 10.1371/journal.pone.0082869. eCollection 2013.

29.

Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa biofilms.

Jensen PØ, Briales A, Brochmann RP, Wang H, Kragh KN, Kolpen M, Hempel C, Bjarnsholt T, Høiby N, Ciofu O.

Pathog Dis. 2014 Apr;70(3):440-3. doi: 10.1111/2049-632X.12120. Epub 2014 Feb 10.

PMID:
24376174
30.

Bactericidal effect of colistin on planktonic Pseudomonas aeruginosa is independent of hydroxyl radical formation.

Brochmann RP, Toft A, Ciofu O, Briales A, Kolpen M, Hempel C, Bjarnsholt T, Høiby N, Jensen PØ.

Int J Antimicrob Agents. 2014 Feb;43(2):140-7. doi: 10.1016/j.ijantimicag.2013.10.015. Epub 2013 Nov 15.

PMID:
24315789
31.

Applying insights from biofilm biology to drug development - can a new approach be developed?

Bjarnsholt T, Ciofu O, Molin S, Givskov M, Høiby N.

Nat Rev Drug Discov. 2013 Oct;12(10):791-808. doi: 10.1038/nrd4000. Review.

PMID:
24080700
32.

Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes.

Jakobsen TH, Hansen MA, Jensen PØ, Hansen L, Riber L, Cockburn A, Kolpen M, Rønne Hansen C, Ridderberg W, Eickhardt S, Hansen M, Kerpedjiev P, Alhede M, Qvortrup K, Burmølle M, Moser C, Kühl M, Ciofu O, Givskov M, Sørensen SJ, Høiby N, Bjarnsholt T.

PLoS One. 2013 Jul 22;8(7):e68484. doi: 10.1371/journal.pone.0068484. Print 2013.

33.

Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa.

Jørgensen KM, Wassermann T, Jensen PØ, Hengzuang W, Molin S, Høiby N, Ciofu O.

Antimicrob Agents Chemother. 2013 Sep;57(9):4215-21. doi: 10.1128/AAC.00493-13. Epub 2013 Jun 17.

34.

P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs.

Ciofu O, Johansen HK, Aanaes K, Wassermann T, Alhede M, von Buchwald C, Høiby N.

J Cyst Fibros. 2013 Dec;12(6):729-36. doi: 10.1016/j.jcf.2013.02.004. Epub 2013 Mar 9.

35.

Respiratory bacterial infections in cystic fibrosis.

Ciofu O, Hansen CR, Høiby N.

Curr Opin Pulm Med. 2013 May;19(3):251-8. doi: 10.1097/MCP.0b013e32835f1afc. Review.

PMID:
23449384
36.

Molecular epidemiology of chronic Pseudomonas aeruginosa airway infections in cystic fibrosis.

Cramer N, Wiehlmann L, Ciofu O, Tamm S, Høiby N, Tümmler B.

PLoS One. 2012;7(11):e50731. doi: 10.1371/journal.pone.0050731. Epub 2012 Nov 28.

37.

Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective.

Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, Molin S.

Nat Rev Microbiol. 2012 Dec;10(12):841-51. doi: 10.1038/nrmicro2907. Epub 2012 Nov 13. Review.

PMID:
23147702
38.

High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms.

Hengzhuang W, Ciofu O, Yang L, Wu H, Song Z, Oliver A, Høiby N.

Antimicrob Agents Chemother. 2013 Jan;57(1):196-204. doi: 10.1128/AAC.01393-12. Epub 2012 Oct 22.

39.

Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.

Ciofu O, Mandsberg LF, Wang H, Høiby N.

FEMS Immunol Med Microbiol. 2012 Jul;65(2):215-25. doi: 10.1111/j.1574-695X.2012.00983.x. Epub 2012 Jun 1. Review. Erratum in: FEMS Immunol Med Microbiol. 2012 Oct;66(1):120.

40.

In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.

Hengzhuang W, Wu H, Ciofu O, Song Z, Høiby N.

Antimicrob Agents Chemother. 2012 May;56(5):2683-90. doi: 10.1128/AAC.06486-11. Epub 2012 Feb 21.

41.

Development of antibiotic resistance and up-regulation of the antimutator gene pfpI in mutator Pseudomonas aeruginosa due to inactivation of two DNA oxidative repair genes (mutY, mutM).

Mandsberg LF, Maciá MD, Bergmann KR, Christiansen LE, Alhede M, Kirkby N, Høiby N, Oliver A, Ciofu O.

FEMS Microbiol Lett. 2011 Nov;324(1):28-37. doi: 10.1111/j.1574-6968.2011.02383.x. Epub 2011 Sep 13.

42.

A complex multilevel attack on Pseudomonas aeruginosa algT/U expression and algT/U activity results in the loss of alginate production.

Sautter R, Ramos D, Schneper L, Ciofu O, Wassermann T, Koh CL, Heydorn A, Hentzer M, Høiby N, Kharazmi A, Molin S, Devries CA, Ohman DE, Mathee K.

Gene. 2012 May 1;498(2):242-53. doi: 10.1016/j.gene.2011.11.005. Epub 2011 Nov 9.

43.

Poor antioxidant status exacerbates oxidative stress and inflammatory response to Pseudomonas aeruginosa lung infection in guinea pigs.

Jensen PØ, Lykkesfeldt J, Bjarnsholt T, Hougen HP, Høiby N, Ciofu O.

Basic Clin Pharmacol Toxicol. 2012 Apr;110(4):353-8. doi: 10.1111/j.1742-7843.2011.00822.x. Epub 2011 Nov 15.

44.

Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates.

Tramper-Stranders GA, van der Ent CK, Molin S, Yang L, Hansen SK, Rau MH, Ciofu O, Johansen HK, Wolfs TF.

Clin Microbiol Infect. 2012 Jun;18(6):567-74. doi: 10.1111/j.1469-0691.2011.03627.x. Epub 2011 Aug 29.

45.

Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection.

Hansen SK, Rau MH, Johansen HK, Ciofu O, Jelsbak L, Yang L, Folkesson A, Jarmer HØ, Aanæs K, von Buchwald C, Høiby N, Molin S.

ISME J. 2012 Jan;6(1):31-45. doi: 10.1038/ismej.2011.83. Epub 2011 Jun 30.

46.

Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms.

Hengzhuang W, Wu H, Ciofu O, Song Z, Høiby N.

Antimicrob Agents Chemother. 2011 Sep;55(9):4469-74. doi: 10.1128/AAC.00126-11. Epub 2011 Jun 13.

47.

Evolutionary dynamics of bacteria in a human host environment.

Yang L, Jelsbak L, Marvig RL, Damkiær S, Workman CT, Rau MH, Hansen SK, Folkesson A, Johansen HK, Ciofu O, Høiby N, Sommer MO, Molin S.

Proc Natl Acad Sci U S A. 2011 May 3;108(18):7481-6. doi: 10.1073/pnas.1018249108. Epub 2011 Apr 25.

48.

Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients.

Lee B, Schjerling CK, Kirkby N, Hoffmann N, Borup R, Molin S, Høiby N, Ciofu O.

APMIS. 2011 Apr;119(4-5):263-74. doi: 10.1111/j.1600-0463.2011.02726.x. Epub 2011 Feb 24.

PMID:
21492226
49.

The clinical impact of bacterial biofilms.

Høiby N, Ciofu O, Johansen HK, Song ZJ, Moser C, Jensen PØ, Molin S, Givskov M, Tolker-Nielsen T, Bjarnsholt T.

Int J Oral Sci. 2011 Apr;3(2):55-65. doi: 10.4248/IJOS11026. Review.

50.

Pseudomonas aeruginosa biofilms in cystic fibrosis.

Høiby N, Ciofu O, Bjarnsholt T.

Future Microbiol. 2010 Nov;5(11):1663-74. doi: 10.2217/fmb.10.125. Review.

PMID:
21133688

Supplemental Content

Support Center